Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

Group 1 - Xeris Biopharma reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and an improvement from a loss of $0.10 per share a year ago, representing an earnings surprise of 57.14% [1] - The company posted revenues of $60.1 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.81%, but showing an increase from year-ago revenues of $44.39 million [2] - Xeris Biopharma shares have increased by approximately 11.2% since the beginning of the year, contrasting with a decline of -0.7% in the S&P 500 [3] Group 2 - The earnings outlook for Xeris Biopharma is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Xeris Biopharma is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $54.1 million, and -$0.22 on revenues of $240.93 million for the current fiscal year [7] Group 3 - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, which may impact stock performance [8] - VAXART, INC., another company in the same industry, is expected to report a quarterly loss of $0.10 per share, reflecting a year-over-year change of +16.7%, with revenues projected at $31.17 million, up 859.1% from the year-ago quarter [9]